Anthracyclines for Breast Cancer? Who Needs Them?
For many patients with early-stage breast cancer, these drugs provide a significant boost to disease-free survival.
Waiting Rooms: A Breast Cancer Story
Laura Yeager talks about her journey with breast cancer, from the fearful thoughts to the free food at chemotherapy.
The Outlook is Hopeful that Biosimilars will Mimic Effectiveness of Original Cancer Drugs for Less Money
Biosimilars are changing the field — and the price — of cancer treatment, though some questions still remain.
Extra Protection: Extended Hormone Therapy Can Reduce Breast Cancer Recurrence
Extending hormonal therapy to 10 years has been found to reduce recurrence in HR-positive breast cancer.
Flesh or Blood? Some Cancer Biopsies May Be Replaced With Genomic Blood Analysis
In some cases, genomic blood analysis may be effective enough to replace cancer biopsies.
The Same, But Different: Biosimilars May Rival Name-Brand Cancer Treatments
Biosimilars are likely to rival name-brand treatments for breast and other cancers, and the competition could drive prices down.
The Cancer Registry Rationale
Joining cancer registries can help patients and the larger oncology community.
Taking the Good With the Bad: Mitigating Heart Problems With Breast Cancer Medication
Herceptin has improved survival for women with HER2-positive breast cancer. Now, scientists are exploring ways to mitigate the heart problems the drug can cause.
That Tingling Feeling: New Therapies Are Evolving for Peripheral Neuropathy
Excitement is growing over new strategies for treating or avoiding peripheral neuropathy in patients with cancer.
Keeping Abreast of Immunotherapy in Breast Cancer
Once considered “immunologically silent,” breast cancer may actually respond to immunotherapy.
Immunotherapy Applicable in Breast Cancer? What Seemed Unlikely Now Holds Promise
